Blog
Inside the New Drug Pipeline
Big Money Bets on a New Generation of Hair-Loss Treatments
Investors are pouring capital into hair-loss research, demonstrating confidence that science may deliver meaningful improvements beyond treatments like minoxidil and finasteride. In the past three months alone, two biotechs have raised at least $270 million. Veradermics, which is developing the first extended-release oral minoxidil, closed an oversubscribed $150 million Series C financing and Pelage Pharmaceuticals secured $120 million in Series B to push its regenerative topical program, PP405.
Post Views: 308
Related Posts
The Topical Finasteride Reality Check
Topical finasteride may reduce scalp DHT and improve hair counts, but “topical” is not the same as “local only.”
Whatever Happened to Hair Cloning?
About Retirement
For decades, hair cloning has been described as the ultimate answer to baldness: take a few healthy follicles, multiply...
Minoxidil Gets a Makeover
New versions minoxidil are moving closer to wider use
New Hope for Teens Facing Sudden Hair Loss
New clinical results suggest that treatments already helping adults with severe alopecia
Is Finasteride Finally Losing Its Grip?
Cosmo Pharmaceuticals has reported positive Phase 3 results for topical clascoterone 5%,
Natural Hair Icon Confronts Hair Loss
Chizi Duru, a trailblazer in the natural-hair movement, recently opened up about her struggle with androgenetic alopecia after years of daily 4C hair care for her YouTube and social media content.
Of Mice and Men… and Minoxidil
Mouse models have long been the silent workhorses of biomedical science—tiny mammals that help unlock big mysteries.
FDA Approval or Marketing HYPE?
What You Should Know About Minoxidil and Finasteride Claims about FDA Approval
Why It Matters
In the increasingly crowded marketplace for hair...
FDA Halts Trial of Hair Loss Drug
Natural Solutions Gaining Traction as Safer Alternatives
The US Food and Drug Administration (US FDA) has recently placed a partial clinical...
Unlocking the Benefits of Oral and Topical Finasteride
Oral finasteride is a prescription medication approved by the United States Food and Drug Administration (FDA). Studies have shown that it can be an effective treatment for male pattern baldness, with a success rate as high as 90%.
Finasteride Spray Expanding
Finjuve Spray with Finasteride from Almirall will shortly be available in Korea after Boryung secured the exclusive rights from Almirall,...
Two is better than one
Researchers Test Minoxidil/Finasteride Combo for FPHL
A double-blind study among 30 postmenopausal women with female pattern hair loss (FPHL) suggests that...